Elan courts shareholders with long-term Tysabri dividend
This article was originally published in Scrip
Elan has thrown another sop to shareholders, apparently aimed at keeping them sweet while it works out its future investment plans and attempts to ward off a takeover bid. It has promised to pay a regular dividend linked to the future royalties it will receive from Biogen Idec on sales of Tysabri (natalizumab), the blockbuster multiple sclerosis drug.
You may also be interested in...
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the format of the content or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.